로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > KIR2DL2

KIR2DL2

요약

Name:Killer cell immunoglobulin-like receptor 2DL2
Target Synonym:CD158b1 Antigen,CD158b,P58.2,Receptors, KIR2DL2,CD158k,Cl-43,p58 NK receptor CL-43,CD158B1,Natural killer-associated transcript 6,NKAT6,Killer cell immunoglobulin-like receptor 2DL2,KIR2DL2,Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 2,Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 2,P58 Natural Killer Cell Receptor Clone CL-43,CD158 Antigen-Like Family Member B1,MHC Class I NK Cell Receptor,NKAT-6
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

제품 리스트 비교 또는 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
KI2-H5255 Human Human KIR2DL2 / CD158b1 / NKAT-6 Protein, Fc Tag
KI2-H5255-structure
KI2-H5255-sds

일부의 생물활성 데이터

KI2-H5255-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Biotinylated Human HLA-C*07:02:01 & B2M & RYR ,His,Avitag™&Tag Free (Cat. No. HLR-H52W2) immobilized on SA Chip can bind Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) with an affinity constant of 1.01 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

KI2-H5255-ELISA
Human KIR2DL2, Fc TagHuman KIR2DL2, Fc Tag (Cat. No. KI2-H5255) ELISA bioactivity

Immobilized Human KIR2DL2, Fc Tag (Cat. No. KI2-H5255) at 1 μg/mL (100 μL/well) can bind Lirilummab with a linear range of 0.1-8 μg/mL (QC tested).

Synonym Name

CD158b1

Background

Killer cell immunoglobulin-like receptor 2DL2(KIR2DL2), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. KIR2DL2 and KIR2DL3, regulate the activation of natural killer cells (NK) by interacting with the human leukocyte antigen-C1 (HLA-C1) group of molecules. KIR2DL2, KIR2DL3 and HLA-C1 are highly polymorphic, with this variation being associated with differences in the onset and progression of some human diseases.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Solid tumours; Leukemia; Squamous Cell Carcinoma of Head and Neck; Leukemia, Lymphoid; Smoldering Multiple Myeloma; Hodgkin Disease; Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details

This web search service is supported by Google Inc.

totop